Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Share-based Compensation (2023 - 2025)

Immunome's Share-based Compensation history spans 3 years, with the latest figure at $7.9 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 44.3% year-over-year to $7.9 million; the TTM value through Dec 2025 reached $25.7 million, up 63.13%, while the annual FY2025 figure was $25.7 million, 63.13% up from the prior year.
  • Share-based Compensation reached $7.9 million in Q4 2025 per IMNM's latest filing, up from $6.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $7.9 million in Q4 2025 to a low of $1.0 million in Q2 2023.
  • Average Share-based Compensation over 3 years is $4.0 million, with a median of $4.1 million recorded in 2024.
  • Peak YoY movement for Share-based Compensation: surged 351.71% in 2024, then skyrocketed 37.92% in 2025.
  • A 3-year view of Share-based Compensation shows it stood at $2.9 million in 2023, then surged by 89.73% to $5.5 million in 2024, then surged by 44.3% to $7.9 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Share-based Compensation are $7.9 million (Q4 2025), $6.7 million (Q3 2025), and $5.3 million (Q2 2025).